Dark chocolate almonds recalled over potentially fatal allergen contamination
The company announced the recall June 13, stating that packages of Frederik's Dark Chocolate Almonds may also contain dark chocolate cashews, according to a press release. Those with a cashew allergy run the risk of experiencing a life-threatening reaction if they consume the product, as the nuts were not declared on the packaging.
Two different packages of Frederik's Dark Chocolate Almonds were affected by the recall: The black stand-up pouches sold at Meijer stores in Michigan, Indiana, Illinois, Ohio, Kentucky, and Wisconsin with a sell-by date of 05/07/2026 or 05/28/2026, and the 8-count, 1.5-ounce multi-pack boxes with a sell-by date of 05/05/2026.
No illnesses have been reported.
Customers who have purchased the product are urged to return it to Meijer to claim a full refund.
Meijer's statement is the latest in a slew of recalls impacting various foods and chains.
Turkana Food Inc issued a recall on 352 cases of its Floria Dried Apricots, according to a press release shared by the U.S. Food and Drug Administration on Thursday. The product was recalled because it contains an undeclared allergen, sulfites, or 'chemicals used as preservatives' added to foods, beverages, and medications to prevent them from spoiling, according to the Cleveland Clinic.
Floria Dried Apricots impacted by the recall were sold at stores in 19 states: Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Maryland, Michigan, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, Texas, and Virginia.
The product has the LOT number 440090478-15-333 on the bottom portion of the packaging. The UPC Label 2539560010 is marked by a sticker on the side of the packaging. The expiration date of November 2026 is also on the bottom of the packaging.
Then, ice cream company Breyers recalled one of its flavors following customer concerns that there was a mislabeling error.
On Tuesday, the United States Food and Drug Administration (FDA) confirmed in a report that 6,668 cases of Breyers Chocolate Truffle Ice Cream were voluntarily recalled by Unilever Manufacturing on June 2 after it was found that the tubs actually contained Rocky Road ice cream.
The Chocolate Truffle flavor has an allergen label that reads, 'may contain tree nuts,' while the Rocky Road flavor declares almonds as one of the ingredients.
In a statement made to People, a representative for Breyers said, 'People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products are our top priority. For more information, consumers can visit www.breyers.com or call 1-800-931-2826.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Theratechnologies shares surge 25% amid $254m Future Pak takeover
Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of the Canadian HIV-specialist biopharma. Via its affiliate CB Biotechnology, US-headquartered Future Pak will purchase shares in Theratechnologies for $3.01 each plus a contingent value right (CVR) of $1.19 on the achievement of future milestones. Shares in Theratechnologies increased 25% at market open following the takeover announcement. The drugmaker has a market cap of $144.6m. The transaction, which will bring the currently Nasdaq-listed Theratechnologies back under private ownership, means Future Pak is paying a cash premium of 126% on the last closing share price for the biopharma. Theratechnologies has two products in the HIV arena that are approved by the US Food and Drug Administration (FDA), namely Egrifta (tesamorelin F8) and Trogarzo (ibalizumab-uiyk). Egrifta is approved to reduce excess visceral abdominal fat in adults with HIV and lipodystrophy while Trogarzo is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistance. Egrifta WR took over from Egrifta SV in March 2025, offering a more convenient formulation. Expected to close in Q4, the deal will close a sale process that has fluctuated over the past year. Future Pak's first attempt to acquire Theratechnologies was rebuffed in August 2024, with the biopharma deeming the $100m offer too low. Future Pak returned to the deal table in January 2025. Theratechnologies had already entered an exclusivity agreement with another potential acquirer, meaning Future Pak was once again turned away. Theratechnologies eventually opened the sale process to other parties, opening the door for a potential deal with the contract manufacturer. In April 2025, Future Pak tabled a $255 offer, which has now been accepted by the drugmaker. Theratechnologies reported 2024 revenue of $85.9m, a 5% increase from the $81.8m accumulated in 2023. Whilst the company reported a positive EBITDA for the year, it struggled with supply for Egrifta WR due to an issue with a contract manufacturer. Still, sales of the drug grew 12%, unlike Trogarzo, which dropped 8% due to 'competitive pressures' in the multidrug-resistant segment of the HIV market. 'This transaction is the result of a thorough and deliberate sale process aimed at maximising value for our shareholders,' stated Frank Holler, Theratechnologies' chair of the board of directors. 'Future Pak's interest in acquiring Theratechnologies represents a vote of confidence in the company we've built, recognising our achievements in bringing innovative medicines to patients and the outstanding contributions of our dedicated employees.' Last year, Future Pak also made multiple unsuccessful attempts to acquire Vanda Pharmaceuticals, the developer of sleep disorder drug Hetlioz. Cycle Therapeutics ultimately won out, acquiring in a $466m deal. "Theratechnologies shares surge 25% amid $254m Future Pak takeover" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Ways to create a dementia-friendly environment during the Fourth of July
LANSING, Mich. (WLNS) — With the Fourth of July approaching quickly, it's important to remember that fireworks celebrations are not for everyone. This includes pets, veterans and those living with dementia. The Alzheimer's Foundation of America (AFA) created the 'F.O.U.R.' steps to creating a dementia-friendly Fourth of July. 'Fireworks and loud noises can create challenges for individuals living with dementia, which is why families need to make thoughtful, proactive adjustments to help their loved ones with dementia celebrate and enjoy Independence Day,' said Jennifer Reeder, LCSW, SIFI, senior director of educational and social services at AFA. 'Being prepared and adaptable are the best ways caregivers can create a dementia-friendly 4th of July for their loved ones.' If someone is a war veteran, AFA says the noises that come from fireworks can be triggering and mistaken for gunshots or bombs. Being inside at times when they are likely to hear fireworks is a good precaution. 'Even if that person is inside, they still may be in an area where fireworks are going off,' Chris Schneider, director of media relations at AFA said. 'That can be leaving the air conditioning on, getting a white noise machine or playing soothing, familiar music. All of that can help muffle some of those sounds.' It can also be helpful to check in on your loved one throughout the night if they live with you. Large crowds can be overwhelming for someone living with dementia. If you are hosting a gathering, limit guests to a few family members and close friends. AFA says name tags could be beneficial. 'Structure the celebration around the person's routine,' Schneider said. 'Routine disruptions can be troubling for someone living with dementia. If they normally eat at a certain time, build that into the day. If they usually take a nap at a certain time, build that into the day.' The AFA says to revise how you celebrate. The organization mentions that living with dementia shouldn't limit how someone celebrates Independence Day. Caregivers could make patriotic decorations and crafts, or look through a family album with pictures of previous Fourth of July celebrations. Both are dementia-friendly activities. Schneider says anyone looking for additional guidance can do so on their website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Los Angeles Times
6 hours ago
- Los Angeles Times
Here's how to get GLP-1 drugs covered by employer health insurance
While the new anti-obesity medications known as GLP-1s are only one tool to combat obesity and cardiometabolic disease, they have changed the medical landscape and are clinically important in treating these diseases. Yet most Americans who have health insurance cannot get coverage for them. For some, the only option has been to resort to compounded drugs for which the Food and Drug Administration has not assured the safety, and for which the main pharmaceutical ingredient is made in Chinese chemical factories without the quality standards of FDA-approved branded drugs. Even that inferior option is going away, as the FDA has declared that the name-brand drugs are no longer in short supply and so the off-brand drugs are no longer allowed. President Trump recently called out 'the fat shot' when he told pharmaceutical companies to offer the United States the same pricing they offer other peer nations. He related a story of a friend in London who told him the price of GLP-1s there is about one-tenth of what it would cost in the U.S. The average listed price in the U.S. is more than $1,000 a month. In England, it is about $150. There is not yet legislative authority to require pharmaceutical companies to sell prescription drugs in the United States at lower prices, but there is a straightforward way that these medications can become affordable to many in the United States. Most employee health insurance coverage is through employer-sponsored plans, in which the budget is based on premiums contributed by both the employer and employee. Few plans provide coverage for any weight loss treatment, but if they did, it would have to fit in that budget — which would probably necessitate raising premiums. Toxic fat is the cause of many cardiometabolic conditions, and GLP-1 drugs can help people reclaim their health. Improving access and affordability could be transformative for public health, given that about 88% of Americans are metabolically unhealthy. Increasingly, employees are telling their employers that they want access to these medications, and many employers would like to offer plans that cover them. The brand-name manufacturers themselves provide a clue to how this could be possible. They offer their drugs directly to patients for around $500 a month. The sticking points? People whose employee-sponsored health insurance would cover even part of the cost of weight loss drugs are not eligible for that reduced price. Also, at $500 a month, even the discounted direct-to-consumer price still makes the drugs unaffordable to many. Drug pricing in the United States is not transparent, and many entities get a share of the dollars that the health plans have budgeted. Simplifying the system with the GLP-1 drugs could make these drugs more accessible. Today, a drug bought from the drug company at $1,000 can include around a $300 rebate negotiated by a pharmacy benefit manager (working on behalf of the employer-sponsored health plan) and is often accompanied by a $150 manufacturer's discount coupon. The resulting price is similar to the around $500 price that drug companies offer directly to patients who don't have coverage for these drugs. If we eliminate the rebates and coupons, so that manufacturers only charge employer-sponsored health plans the same $500 price they charge consumers directly, and then allow employers to contribute part of the cost (say $300 a month), we can get the out-of-pocket costs for employees close to the price at which these drugs are sold in other countries. It would be a rebate-free, coupon-free system with reasonable cost sharing by the employer. The only reason that system of rebates even came to exist was to create enticements so certain manufacturers could persuade pharmacy benefit managers and employee-sponsored health plans to favor their drug over others'. But in this case, where only two main drugs exist and both have publicly available clinical trial data that physicians can use to make informed prescribing decisions, rebates aren't needed. In reality, recent agreements between pharmacy benefit managers and drug manufacturers have prioritized financial interests over clinical appropriateness, determining drug preference based on what benefits the companies, not what's best for the patient. Getting the price of the drugs to an affordable level would significantly remove one of the most despised aspects of the healthcare system — prior approval authorization. Doctors' offices are expending resources to get around barriers erected to limit the use of healthcare plan dollars on expensive medications for those the insurance plan and its managers determine do not need the drug, even when the doctors believe they do. GLP-1s are highly effective for most people, but they also have some serious risks. We should leave it to doctors to make shared decisions with their patients about whether the risks outweigh the benefits. To further create incentives for the pharmaceutical companies to reduce their prices and for employers to share in the cost of these drugs, the Trump administration should agree, as the Biden administration did, to cover them under Medicare. (Trump reversed that effort this year, barring Medicare and Medicaid from using them to treat the disease of obesity.) This plan to simplify payments and expand access would not make all drugs affordable in the United States, but increasing accessibility to GLP-1s can get us on the road to eliminating the significant problem of cardiometabolic disease and improving our health. David A. Kessler, a former commissioner of the Food and Drug Administration, is the author of 'Diet, Drugs, and Dopamine: The New Science of Achieving a Healthy Weight.'
